Richter announces approval in Japan of its licensed-out biosimilar teriparatide


Hungarian drug maker Gedeon Richter said Japanese authorities cleared the biosimilar teriparatide, developed by its German joint venture Richter Helm BioTec, for the treatment of osteoporosis. Japan’s Ministry of Health, Labour and Welfare issued marketing authorisation for the drug to Richter’s local licence partner Mochida Pharmaceutical.

The European Commission approved teriparatide in January 2017 and the product was launched in Europe, under the brand Terrosa, in August 2019, after the patent of the reference product expired.



Leave a Reply

Your email address will not be published. Required fields are marked *